MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer
24 Junho 2024 - 1:00PM
Business Wire
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage
biotechnology company and a leader in the development of Microbiome
Ecosystem TherapiesTM (MET) dedicated to enhancing survival for
patients with cancer, today announced the appointment of Gianfranco
Pittari, M.D., Ph.D., as Chief Medical Officer. Dr. Pittari brings
over 15 years of international experience in clinical research and
drug development in hematology, oncology, and immunology. He will
join the executive management team and oversee the clinical
programs of the Company’s innovative microbiome-based drug
candidates.
“We are very pleased to welcome Gianfranco to MaaT Pharma. With
his extensive experience leading clinical studies from early
development through late-stage trials, he is a valuable addition to
MaaT Pharma’s team during this critical period of growth as our
lead asset, MaaT013, nears Phase 3 trial completion,” said Hervé
Affagard, Chief Executive Officer and co-founder of MaaT Pharma.
“Dr. Pittari’s international background strengthens our growing
global team, reinforcing our expertise to excel in serving patients
worldwide.”
Dr. Pittari has extensive medical experience in drug
development, particularly in oncology and hematology. His clinical
work includes leading successful Phase I-III clinical trials at
Celgene Corporation - Bristol Myers Squibb, where he was
instrumental in the development of the first CAR T cell therapy for
Multiple Myeloma (Abecma® - idecabtagene vicleucel), currently
approved in both the US and the EU for use in earlier lines of
treatment in patients with relapsed and refractory disease. Before
joining MaaT Pharma, he served as Executive Medical Director at
Autolus, a clinical-stage biopharmaceutical company developing
next-generation, programmed T Cell therapies treating cancer and
autoimmune disease. He also held the position of Senior Consultant
Hematology-BMT at the National Center for Cancer Care and Research
in the State of Qatar, a leading international hub providing
state-of-the-art clinical care, where he treated patients with
hematological conditions and took part in multiple academic
initiatives.
“I am inspired by MaaT Pharma’s ambition and vision to serve
physicians and bring innovative treatments to patients with high
unmet needs in oncology,” stated Dr. Pittari, Chief Medical
Officer. “I look forward to bringing my experience to support the
team and contributing to the advancement of our microbiome drug
candidates to help patients with cancer.”
Dr. Pittari holds an M.D. degree from the University of Pavia,
completed a Hematology fellowship at the University of Parma, and
earned a Ph.D. in Immunology from Paris-Sud University. He has also
conducted extensive academic research at both Gustave Roussy and
Memorial Sloan-Kettering Cancer Center.
About MaaT Pharma
MaaT Pharma, a clinical-stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single-arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240624452987/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications Jacob VERGHESE or Desmond JAMES
+49 151 7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Maat Pharma (EU:MAAT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024